• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

    6/3/23 8:17:00 PM ET
    $CWBR
    $GHL
    $PDCE
    $VECT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $CWBR alert in real time by email

    NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) --

    CohBar, Inc. (NASDAQ:CWBR)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company.

    If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Greenhill & Co., Inc. (NYSE:GHL)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of GHL to Mizuho Financial Group, Inc. for $15.00 per share in cash.

    If you are a GHL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    PDC Energy, Inc. (NASDAQ:PDCE)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of PDCE and Chevron Corporation. Under the terms of the proposed merger, PDCE shareholders will receive 0.4638 shares of Chevron Corporation common stock for each share of PDCE owned.

    If you are a PDCE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    VectivBio Holding AG (NASDAQ:VECT)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of VECT to Ironwood Pharmaceuticals, Inc. for $17.00 per share in cash.

    If you are a VECT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

    Contact:

    Joshua M. Lifshitz, Esq.

    Lifshitz Law PLLC

    Phone: 516-493-9780

    Facsimile: 516-280-7376

    Email: [email protected]



    Get the next $CWBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CWBR
    $GHL
    $PDCE
    $VECT

    CompanyDatePrice TargetRatingAnalyst
    PDC Energy Inc.
    $PDCE
    5/31/2023Buy → Neutral
    Seaport Research Partners
    PDC Energy Inc.
    $PDCE
    1/10/2023$97.00Buy
    Mizuho
    VectivBio Holding AG
    $VECT
    12/13/2022$18.00Buy
    Jefferies
    PDC Energy Inc.
    $PDCE
    12/12/2022$68.00Buy → Hold
    Truist
    PDC Energy Inc.
    $PDCE
    10/18/2022$74.00Buy → Neutral
    Goldman
    PDC Energy Inc.
    $PDCE
    9/20/2022Sector Weight
    KeyBanc Capital Markets
    PDC Energy Inc.
    $PDCE
    7/20/2022$76.00Buy
    MKM Partners
    VectivBio Holding AG
    $VECT
    7/1/2022$23.00Overweight
    Piper Sandler
    More analyst ratings

    $CWBR
    $GHL
    $PDCE
    $VECT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ferro Kevin returned 81,495 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:08:03 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Wyles David returned 98,707 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:05:56 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Ekman Ulrika returned 10,205 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:03:36 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance

    $CWBR
    $GHL
    $PDCE
    $VECT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Land & Buildings Nominates Two Independent Candidates – Jim Hoffmann and Adam Troso – for Board of National Health Investors

      Believes That Incremental Changes Since Last Annual Meeting Are Insufficient to Address the Poor Corporate Governance and Concerning Conflicts of Interest Threatening to Prevent NHI From Reaching its Full Value Potential Highlights the Urgent Need for NHI to Have Truly Independent Directors With the Right Expertise in the Boardroom Given Ongoing Lease Renewal Negotiations With Major Tenant National Healthcare Corp (NHC) Details Concerns That NHC Lease Negotiations Will Not Reflect Market Value Given Board Member Conflicts; Lease Likely Has 75% Upside Based on Strong Coverage and Precedent Transactions and Could Boost Earnings 13% Or More Believes NHI Shares Have 50% Upside Over the Next

      2/19/25 8:00:00 AM ET
      $DOC
      $GHL
      $HCP
      $ING
      Real Estate Investment Trusts
      Real Estate
      Investment Bankers/Brokers/Service
      Finance
    • Memo Therapeutics AG appoints Paul Carter as Chairperson

      PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

      7/8/24 7:00:00 AM ET
      $IMTX
      $IRWD
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations